U.S., March 31 -- ClinicalTrials.gov registry received information related to the study (NCT07500467) titled 'Upadacitinib for Refractory Takayasu Arteritis' on March 24.
Brief Summary: Takayasu arteritis (TKA) is an autoimmune vasculitis characterized with involvement of aorta and its primary branches.Upadacitinib is an oral, selective JAK1 inhibitor that potently inhibits JAK1 activity, representing a potential therapeutic option.This study aims to assess the efficacy and safety of upadacitinib in refractory Takayasu arteritis.
Study Start Date: March 19, 2024
Study Type: OBSERVATIONAL
Condition:
Takayasu Arteritis
Recruitment Status: COMPLETED
Sponsor: Liu Tian
Information provided by (Responsible Party): Liu Tian, Peking Univers...